IP Library Granted Patent US 10,285,957
Granted Patent B2
US 10,285,957 · App. 15/685,702 · Granted May 14, 2019

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,285,957
App. No.
15/685,702
Granted
May 14, 2019
Kind
B2
Abstract

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Claims (42)

1. A method for preparing a pharmaceutical composition, the method comprising:

(a) preparing an aqueous composition consisting of:

(a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;

(a2) at least one metal chelator;

(a3) optionally, at least one anesthetic;

(a4) optionally, at least one non-steroid anti-inflammatory drug; and

(a5) a quantity of sterile water,

wherein the composition is optionally free of sulfites and is free of preservatives; and

(b) lyophilizing the aqueous composition,

to obtain thereby the lyophilized pharmaceutical composition, wherein the lyophilization of the aqueous composition is carried out in a bicameral container comprising a first section comprising the lyophilized pharmaceutical composition, a second section comprising a carrier comprising water, a partition separating the first and second sections, and a moveable plunger wherein the moveable plunger is capable of opening the partition when pressure is applied to the moveable plunger and thereby to the carrier.

2. The method of claim 1 , further comprising adding to the lyophilized composition a quantity of sterile water prior to the use thereof,

to obtain thereby a re-constituted pharmaceutical composition.

3. The method of claim 1 , wherein the method is carried out in the bicameral container comprising a first section and a second section separated by a partition.

4. The method of claim 3 , further comprising:

(a) filling the first section with a quantity of the lyophilized composition;

(b) filling the second section with a quantity of sterilized water; and

(c) eliminating the partition to allow the contents of the first and second sections to mix,

to obtain thereby the pharmaceutical composition to be administered to a patient.

5. A kit, comprising the bicameral container of claim 3 , wherein the first section is filled with a quantity of the lyophilized composition and the second section is filled with a quantity of sterilized water.

6. The method of claim 1 , further comprising combining the lyophilized composition, prior to the use thereof, with the aqueous composition and, optionally, with an additional quantity of sterile water,

to obtain thereby the pharmaceutical composition in a liquid form.

7. The method of claim 1 , wherein epinephrine is in the form of epinephrine hydrochloride.

8. The method of claim 1 , wherein the metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.

10. The method of claim 1 , wherein the anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

11. The method of claim 1 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

12. The method of claim 1 , wherein the aqueous composition further comprises a trace amount of a sulfite or preservative, wherein the sulfite or preservative is present at a concentration less than about 1 μM.

13. The method of claim 1 , wherein the bicameral container is capable of administering the pharmaceutical composition as drops.

14. The method of claim 1 , wherein the bicameral container is capable of administering the pharmaceutical composition by intraocular injection.

15. The method of claim 1 , wherein the partition is a one way valve.

16. The method of claim 15 , wherein the moveable plunger opens the one way valve when pressure is applied to the moveable plunger and thereby to the carrier.

17. The method of claim 1 , wherein the moveable plunger comprises a protrusion or puncture component that pierces the partition when pressure is applied to the moveable plunger and thereby to the carrier.

18. A method for preparing a pharmaceutical composition, the method comprising:

(a) preparing an aqueous composition consisting of:

(a1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;

(a2) at least one metal chelator;

(a3) optionally, at least one anesthetic;

(a4) optionally, at least one non-steroid anti-inflammatory drug; and

(a5) a quantity of sterile water,

wherein the composition is optionally free of sulfites and is free of preservatives; and

(b) lyophilizing the aqueous composition,

to obtain thereby the lyophilized pharmaceutical composition, wherein the lyophilization of the aqueous composition is carried out in a bicameral reconstitution means.

Assignments (9)
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556 Recorded Mar 30, 2023
From: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
To: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
Reel/Frame 063205/0889 →
SECURITY INTEREST Recorded Dec 15, 2022
From: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
To: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 062105/0556 →
RELEASE OF SECURITY INTEREST Recorded May 7, 2021
From: SWK FUNDING LLC
To: HARROW IP, LLC
Reel/Frame 056174/0332 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 21, 2019
From: HARROW IP, LLC
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 051079/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2019
From: IMPRIMIS PHARMACEUTICALS, INC.
To: HARROW IP, LLC
Reel/Frame 050946/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: KAROLCHYK, JOHN SCOTT; BAUM, MARK L.
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 047827/0794 →
Cited By (1)
US 12,702,651